Kate Middleton in her recent video address declared that she
was receiving preventative chemotherapy. There was a little debate regarding what
this might have meant but has broadly been taken to indicate adjuvant chemotherapy.
This is a type of strategy, where chemotherapy for cancer is given in conjunction
with another form of treatment such as radiotherapy or surgery in this case.
The adjuvant therapy is often regarding as the secondary treatment as it may be
less effective or less established than the primary treatment. The rational is
to mop up any residual microscopic disease and reduce the risk of recurrence. Chemotherapy
has been traditionally used in advanced diseases where surgery or radiotherapy
may not be curative, however this is no longer the case and cancer treatment are
often multimodal. If a combination of treatment is more effective than a single
treatment, then their use may be justified if the benefits of additional survival
outweigh any detrimental effects on quality of life.
There is plenty of research on adjuvant treatments. The
progress in these areas have often outstripped developments made in surgery in
recent years. Though surgery alone, by and large, remains the most effective
treatment for cancer in many cases.
It is natural to want to trial and develop new compounds in
the fight against cancer in addition to extending the application of existing
chemotherapy regimens. Over the last few years an average of just under 5000 articles
have been published on adjuvant chemotherapy.
There are many examples of adjuvant chemotherapy.
Here are a few:
Testicular Cancer,
Chemotherapy may be given after the removal of the testes in
patients with testicular cancer and no signs of diseases outside of the testes,
i.e. no remaining visible disease after surgery cisplatin may be given in
combination with other drugs and this can reduce the chance of cancer
reappearing in the lymph nodes in the abdomen after surgery.
Bladder Cancer,
Drugs may be instilled into the bladder which reduces the
chance of bladder cancer reappearing in the bladder after successful treatment.
Examples are mitomycin and BCG. These are localised treatments that generally have
no widespread effect on the body.
Breast Cancer:
"Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01Trial" The PACS 01 trial demonstrated improved disease-free survival
(DFS) and overall survival (OS) rates with sequential adjuvant epirubicin-based
and docetaxel chemotherapy compared to conventional chemotherapy regimens. This
regimen is now a standard of care for many breast cancer patients.
Colon Cancer:
"Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer" (The MOSAIC trial) The MOSAIC trial
demonstrated that FOLFOX significantly improved disease-free survival compared
to fluorouracil and leucovorin alone. This regimen is now a standard adjuvant
treatment for stage III colon cancer.
Lung Cancer (Non-Small Cell):
Adjuvant Chemotherapy for Completely Resected Stage II andIII Non–Small-Cell Lung Cancer" (The LACE Meta-analysis). The LACE
meta-analysis showed that adjuvant chemotherapy with cisplatin or
carboplatin-based regimens improved overall survival in patients with
completely resected stage II and III non-small-cell lung cancer.
Ovarian Cancer:
Adjuvant Chemotherapy in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" Meta-analyses have
consistently shown that adjuvant chemotherapy with carboplatin and paclitaxel
significantly improves progression-free survival and overall survival in
patients with ovarian cancer.
Stomach Cancer (Gastric Cancer):
Adjuvant Chemotherapy for Gastric Cancer with S-1, an OralFluoropyrimidine" (The ACTS-GC trial) The ACTS-GC trial in Japan showed
that adjuvant chemotherapy with S-1, an oral fluoropyrimidine, significantly
improved overall survival compared to surgery alone in patients with stage II
or III gastric cancer.
Prostate Cancer:
Docetaxel and Prednisone or Mitoxantrone and Prednisone for Advanced Prostate Cancer The CHAARTED trial demonstrated a significant
improvement in overall survival with the addition of docetaxel to standard
androgen deprivation therapy in men with metastatic hormone-sensitive prostate
cancer.
These are just a few examples, and the choice of adjuvant
chemotherapy can vary based on the specific characteristics of the cancer and
the patient.